Eraldo O. Bucci

TL;DR: 5-FU can affect, both at the cellular and molecular levels, two key cell types of the cardiovascular system, potentially explaining some manifestations of 5-FU-induced cardiovascular toxicity.

TL;DR: It is found that adenocarcinoma patients (pT1-4) with higher TLR-4 expression in stromal compartment had a significantly increased risk in disease progression and those with a diagnosis of pT3 (33 cases) colon cancer, those with very high levels of TLr-4 in the tumor stroma relapsed significantly earlier than those with lower expression levels.

TL;DR: The differences in cardiovascular effects of these two compounds are somewhat unexpected and suggest distinct mechanisms of action, which have clear implications in clinical application and prevention of cardiotoxicity in cardio-oncological approaches.

TL;DR: It is confirmed that fluoropyrimidine cardiotoxicity is an infrequent but documented side effect and oncology patients under treatment should be closely observed and monitored for cardiac symptoms with particular attention in case of signs or symptoms of cardiovascular complications.

TL;DR: It is suggested that elevated levels of soluble adhesion molecules and TNF-alpha in the blood of IL-2-treated patients may arise from a systemic inflammatory reaction producing endothelial cell activation.